Patents by Inventor Ianina Valenta

Ianina Valenta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
    Patent number: 10105447
    Abstract: Modified canine leptin polypeptides and formulations and uses thereof, are provided including polyethylene glycol (PEG) modified canine leptin polypeptides, wherein the PEG moiety is covalently attached to a para-acetyl-phenylalanine (pAF) residue of the polypeptide, and related compositions and methods useful in treating companion animal obesity and other leptin-related disorders.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 23, 2018
    Assignees: ELANCO US INC., AMBRX, INC.
    Inventors: Michael Bledsoe, Peter Connor Canning, Michael Deguzman, Nick Knudsen, Ianina Valenta
  • MODIFIED CANINE LEPTIN POLYPEPTIDES
    Publication number: 20150366983
    Abstract: Modified canine leptin polypeptides and formulations and uses thereof, are provided including polyethylene glycol (PEG) modified canine leptin polypeptides, wherein the PEG moiety is covalently attached to a para-acetyl-phenylalanine (pAF) residue of the polypeptide, and related compositions and methods useful in treating companion animal obesity and other leptin-related disorders.
    Type: Application
    Filed: March 12, 2014
    Publication date: December 24, 2015
    Inventors: Michael BLEDSOE, Peter Connor CANNING, Michael DEGUZMAN, Nick KNUDSEN, Ianina VALENTA
  • Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives
    Publication number: 20150080559
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: May 24, 2012
    Publication date: March 19, 2015
    Applicant: AMBRX, INC.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Mardsen, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Ianina Valenta